The SMTA 2 is a legally-binding contract between WHO and a company, laboratory or other institution within the PIP Framework, and it establishes a structured process for an efficient and equitable access to vaccines and antivirals by all countries at the time of a pandemic. To date (June 2017) WHO has concluded 11 agreements with vaccine and antiviral manufacturers and through these SMTA2s has secured approximately four times the amount of pandemic vaccine available during the H1N1 pandemic.

Meaning: 
Standard Material Transfer Agreement-2
Type of acronyms: 
Mechanism
Category of acronyms: 
IFPMA
Alphabets: 
S